Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Study:

Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells

Rationale:

Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.

Purpose:

Phase I trial to study the effectiveness of amifostine plus combination chemotherapy in treating patients with advanced cancer.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Chronic Myeloproliferative Disorders
Drug/Agent Toxicity by Tissue/Organ
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific
Biological: sargramostim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: cyclophosphamide
Phase 1

Verified by The Cleveland Clinic May, 2007

Sponsored by: The Cleveland Clinic
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00004036

Study Type: Interventional

Study Design: Primary Purpose: Supportive Care

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

George Thomas Budd, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site